Can Intranasal Insulin Improve Cognitive Outcomes in Diabetes?
La Nouvelle Orleans Ballroom C
Level 2, Ernest N. Morial Convention Center
Q&A with Vera Novak, MD, PhD
Associate Professor of Neurology (Emeritus),
Beth Israel Deaconess Medical Center, Harvard Medical School
What is your presentation about?
Type 2 diabetes accelerates brain aging and increases the risk for dementia. Intranasal insulin has emerged as a potential treatment for cognitive and functional decline associated with aging, insulin resistance and diabetes. Memory Advancement with Intranasal Insulin (MemAID) trial evaluated the long-term effects of intranasal insulin therapy in older people with type 2 diabetes as compared to placebo and non-diabetic controls, and provided evidence for preliminary safety and efficacy of intranasal insulin therapy for age-related cognitive and gait decline.
What makes this topic important in 2022?
There are over 44 million people living with diabetes, and over 80 million people with prediabetes. Improvement of functional outcomes may have a significant impact on their quality of life.
How did you become involved with this area of diabetes research or care?
We have observed the impact of diabetes on the brains of older adults, for which there was no cure, and therefore we started to look for new solutions.
What are you most looking forward to at the 82nd Scientific Sessions?
Exciting topics, lectures and interactions with colleagues.